Compare KOSS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOSS | CNTB |
|---|---|---|
| Founded | 1953 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.3M | 135.7M |
| IPO Year | 1994 | 2020 |
| Metric | KOSS | CNTB |
|---|---|---|
| Price | $3.99 | $2.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 20.2K | ★ 416.0K |
| Earning Date | 05-08-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,624,170.00 | $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $3.50 | $1.23 |
| 52 Week High | $8.59 | $3.82 |
| Indicator | KOSS | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 48.06 | 56.27 |
| Support Level | $3.77 | $2.30 |
| Resistance Level | $4.19 | $2.68 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 44.44 | 84.54 |
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.